Trials
3 active
7 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a 100 mg single oral dose of casdatifan.”In the company’s words, NCT07751250 on ClinicalTrials.gov
- Tested for
- Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Hepatic Impairment, Clear Cell Renal Cell Carcinoma, Solid Tumors
- Main trialPhase 3
- “The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.”In the company’s words, NCT07011719 on ClinicalTrials.gov
- Other names
- AB521
Other drugs for Advanced Clear Cell Renal Cell Carcinoma
- BCD-217Biocad · Phase 3
- ProlgolimabBiocad · Phase 3
- BalstilimabAgenus Inc. · Phase 2
- BotensilimabAgenus Inc. · Phase 2
- SYS6088CSPC · Phase 1/2
- GB268Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2
Coming up3
- May 2027Phase 1 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Mar 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Apr 2028 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | |
| Phase 1Recruiting | May 2027 | Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function | |
| Phase 1Recruiting | Mar 2029 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | |
| Phase 1Completed | 17 Feb 2023 | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers | |
| Phase 1Completed | 31 Oct 2023 | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers | |
| Phase 1Completed | 18 Oct 2025 | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) | |
| Phase 1Completed | 3 Jul 2026 | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026